Author (Year) | Design /Study Size | Treatment being studied | Mean (Year) | Findings (refer to Figures 2-5) |
Anticoagulant therapy and incidence of stroke | ||||
Patel, M. R. et al. (2011) | Randomized Clinical trial (n = 14,264) | Rivaroxaban (Xarelto) 20 mg or 15 mg daily for patients with a creatinine clearance of 30 to 49 mL per minute vs. dose adjusted (target international normalized ratio [INR], 2.0 to 3.0) Warfarin | 71.2 ± 9.42 (73 years (1/4 of patients were 78 years and older) and 39.7% of the patients were women) | Rivaroxaban was noninferior to Warfarin. Stroke or systemic embolism occurred in 269 patients in the rivaroxaban group and in 306 patients in the warfarin group (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P < 0.001 for noninferiority; P = 0.12 for superiority) [12] . |
Rutherford, O. C. W. et al. (2020) | Randomized cohort trial (n = 20,504) | Dabigatranvsrivaroxaban | Dabigatran 70.9 ± 10.95 Rivaroxaban 70.9 ± 11.21 | Stroke/SE occurred with an event rate of 1.84/100 person-years compared with 2.21/100 person-years in the rivaroxaban group [HR 0.88; 95% confidence interval (CI) 0.76 - 1.02]. |